BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Medtronic
Boehringer Ingelheim
Moodys
Novartis
US Department of Justice
McKesson
AstraZeneca
Merck
Covington

Generated: January 16, 2018

DrugPatentWatch Database Preview

DYNACIRC Drug Profile

« Back to Dashboard

When do Dynacirc patents expire, and what generic alternatives are available?

Dynacirc is a drug marketed by Smithkline Beecham and Glaxosmithkline Llc and is included in two NDAs.

The generic ingredient in DYNACIRC is isradipine. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the isradipine profile page.
Drug patent expirations by year for DYNACIRC
Medical Subject Heading (MeSH) Categories for DYNACIRC

US Patents and Regulatory Information for DYNACIRC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Smithkline Beecham DYNACIRC isradipine CAPSULE;ORAL 019546-001 Dec 20, 1990 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Llc DYNACIRC CR isradipine TABLET, EXTENDED RELEASE;ORAL 020336-002 Jun 1, 1994 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Smithkline Beecham DYNACIRC isradipine CAPSULE;ORAL 019546-002 Dec 20, 1990 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Llc DYNACIRC CR isradipine TABLET, EXTENDED RELEASE;ORAL 020336-001 Jun 1, 1994 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for DYNACIRC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline Beecham DYNACIRC isradipine CAPSULE;ORAL 019546-001 Dec 20, 1990 ➤ Subscribe ➤ Subscribe
Smithkline Beecham DYNACIRC isradipine CAPSULE;ORAL 019546-002 Dec 20, 1990 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
McKesson
Baxter
Boehringer Ingelheim
Argus Health
Citi
Accenture
Queensland Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot